Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 1
1(33.3%)
N/A
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01240343Completed

Creation of the Biobank Related to Eye Disease

Role: collaborator

NCT01232777Phase 2Withdrawn

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

Role: lead

NCT01256632Not ApplicableCompleted

Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy

Role: lead

NCT00702819Phase 1Terminated

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

Role: lead

All 4 trials loaded